FLNA
Filana Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
—
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Filana Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
—
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Filana Therapeutics has 7 disclosed suppliers and 0 disclosed customers in SEC filings.
SentenceIn 2021, we entered into an agreement with Evonik Corporation to supply clinical-grade quantities of drug substance for simufilam.
FLNA 10-Kaccession 0001437749-26-007962
SentenceWe have a drug supply agreement with Evonik Industries AG for simufilam.
FLNA 10-Kaccession 0001437749-26-007962
SentenceThis study was funded in part by a research grant award from NIH.
FLNA 10-Kaccession 0001437749-26-007962
SentenceThe study was conducted by PsychoGenics, Inc., the TSC Preclinical Consortium's research partner.
FLNA 10-Kaccession 0001437749-26-007962
SentenceThe study was conducted in collaboration with the TSCA and the TSC Preclinical Consortium using an animal model of TSC-related epilepsy, the Tsc1 conditional knockout (CKO) mouse line ( Tsc1 -CKO).
FLNA 10-Kaccession 0001437749-26-007962
SentenceThe study was conducted in collaboration with the TSCA and the TSC Preclinical Consortium using an animal model of TSC-related epilepsy, the Tsc1 conditional knockout (CKO) mouse line ( Tsc1 -CKO).
FLNA 10-Kaccession 0001437749-26-007962
SentenceIn addition to our owned intellectual property, on February 26, 2025, we entered into a License Agreement (the "License Agreement") with Yale University ("Yale") pursuant to which we were granted exclusive worldwide rights, with rights to sublicense, to Yale's interest in certain patent and other intellectual property rights that could be useful or necessary to the development and commercialization of simufilam for the treatment of TSC‑related epilepsy and other potential indications.
FLNA 10-Kaccession 0001437749-26-007962
—
—
Filana Therapeutics, Inc.
0.62
−0.04 · −5.76%
post 0.63 +2.31%
Expected move
No implied move.